Browse our anti-CDKN2B (CDKN2B) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) Antibodies (CDKN2B)
On are 140 Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) Antibodies from 21 different suppliers available. Additionally we are shipping CDKN2B Proteins (7) and CDKN2B Kits (2) and many more products for this protein. A total of 159 CDKN2B products are currently listed.
AV083695, CDK4I, cdk4l, CDKN2A, INK4b, MTS2, p14-INK4b, P15, p15(INK4b), p15INK4b, TP15
list all antibodies Gene Name GeneID UniProt
CDKN2B 1030 P42772
CDKN2B 12579 P55271
CDKN2B 25164 P55272

Show all species

Show all synonyms

Most Popular Reactivities for anti-CDKN2B (CDKN2B) Antibodies

Select your species and application

anti-Human CDKN2B Antibodies:

anti-Mouse (Murine) CDKN2B Antibodies:

anti-Rat (Rattus) CDKN2B Antibodies:

All available anti-CDKN2B Antibodies

Go to our pre-filtered search.

Top referenced anti-CDKN2B Antibodies

  1. Mouse (Murine) Polyclonal CDKN2B Primary Antibody for IF - ABIN181357 : Franklin, Xiong: Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. in Molecular biology of the cell 1997 (PubMed)

  2. Dog (Canine) Polyclonal CDKN2B Primary Antibody for WB - ABIN2774603 : Scott, Kimura, Dong, Ichinohasama, Bergen, Kerviche, Sheridan, DeCoteau: Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. in Leukemia research 2004 (PubMed)

  3. Human Polyclonal CDKN2B Primary Antibody for ELISA, WB - ABIN4342269 : Geyer: Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia. in Epigenetics 2010 (PubMed)

  4. Human Monoclonal CDKN2B Primary Antibody for IF, IP - ABIN1449282 : Hannon, Beach: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. in Nature 1994 (PubMed)

  5. Human Polyclonal CDKN2B Primary Antibody for ICC, IF - ABIN407770 : Siddiqi, Terry, Matushansky: Hiwi mediated tumorigenesis is associated with DNA hypermethylation. in PLoS ONE 2012 (PubMed)

More Antibodies against CDKN2B Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) interaction partners

  1. These data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma.

  2. Here we present, as far as we are aware, the first case of metastatic microcystic adnexal carcinoma with DNA sequencing results indicating a mutation in TP53 (show TP53 Antibodies) and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A (show CDKN2A Antibodies)) and cyclin dependent kinase inhibitor 2B (CDKN2B).

  3. results provide evidence for the influence of genetic variants at CDKN2A (show CDKN2A Antibodies)/B locus with the risk of developing B-AL

  4. Case Report: knee joint malignant tenosynovial giant cell tumor with CDKN2A (show CDKN2A Antibodies)/B genomic alteration.

  5. Total 1208 differentially expressed genes were screened, and 5 coronary artery disease (CAD (show CAD Antibodies))-associated miRNAs (including miR (show MLXIP Antibodies)-92a) were predicted associated with CAD (show CAD Antibodies). The SVM classifier was constructed based on the 41 featured genes and had high recognition efficiency. Only one lncRNA CDKN2B-antisense targeting miR (show MLXIP Antibodies)-92a was obtained.

  6. In a suspicious INK4b-ARF-INK4a (show CDKN2A Antibodies) gene cluster at chromosome 9p21 in uveal melanoma cells, aberrant INK4a (show CDKN2A Antibodies) and INK4b defects were simultaneously endogenously auto-corrected after targeting the suppression of abnormal ANRIL lncRNA.

  7. Upregulation of ZEB1-AS1 colorectal cancer promotes cell proliferation and inhibits cell apoptosis. In addition, cell cycle inhibitory protein p15 participates in the oncogenic function of ZEB1-AS1. Collectively, ZEB1-AS1 has asignificant effect on colorectal cancer pathological process and serves as a valuable prognostic biomarker for colorectal cancer.

  8. Genetic association analyses using the cpRNFLT with 768 points suggest that the CDKN2B gene was associated with paracentral/lower hemifield scotomas.

  9. We found that CDKN2B was a virtual target of miR (show MLXIP Antibodies)-15a-5p with potential binding sites in the 3'UTR (show UTS2R Antibodies) of CDKN2B (77-83 bp). We also showed that miR (show MLXIP Antibodies)-15a-5p could bind to the CDKN2B 3'UTR (show UTS2R Antibodies). The data revealed a negative regulatory role of miR (show MLXIP Antibodies)-15a-5p in the apoptosis of smooth muscle cells via targeting CDKN2B, and showed that miR (show MLXIP Antibodies)-15a-5p could be a novel therapeutic target of AAA (show APP Antibodies).

  10. Meta-analysis indicates that CDKN2B gene rs1063192 polymorphism is significantly associated with a decreased risk of glaucoma. [meta-analysis]

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) interaction partners

  1. Data show that the Wnt (show WNT2 Antibodies)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (show HNF1A Antibodies)) is recruited to and triggers transcription of the Ink4/Arf (show CDKN2A Antibodies) tumor suppressor locus, such as as p15Ink4b, p16Ink4a (show CDKN2A Antibodies) and p19Arf (show CDKN2A Antibodies).

  2. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a (show CDKN2A Antibodies)/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  3. Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta (show TGFB1 Antibodies) signaling and hypoxic neovessel maturation.

  4. Control of CD8 (show CD8A Antibodies) T cell proliferation and terminal differentiation by active STAT5 (show STAT5A Antibodies) and CDKN2A/CDKN2B.

  5. Radiation-induced double strand breaks cooperate with loss of Ink4 (show CDKN2A Antibodies) and Arf (show CDKN2A Antibodies) tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.

  6. When overexpressed in naked mole rat or human cells, pALT(INK4a (show CDKN2A Antibodies)/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a (show CDKN2A Antibodies)).

  7. Cdk4 (show CDK4 Antibodies) and Cdk6 (show CDK6 Antibodies) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (show CDK6 Antibodies) in sequestering INK4 (show CDKN2A Antibodies) proteins away from Cdk4 (show CDK4 Antibodies).

  8. Data indicate that loss of cyclin-dependent kinase inhibitor p15 (p15Ink4b) collaborates with oncogene (show RAB1A Antibodies) fusion protein Nup98 (show NUP98 Antibodies)-HoxD13 (show HOXD13 Antibodies) transgene in the development of predominantly myeloid neoplasms.

  9. Loss of CDKN2B promotes atherosclerosis by increasing the size and complexity of the lipid-laden necrotic core through impaired efferocytosis.

  10. Meningioma progression in mice triggered by Nf2 (show NF2 Antibodies) and Cdkn2ab inactivation.

CDKN2B Antigen Profile

Antigen Summary

This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.

Alternative names and synonyms associated with CDKN2B

  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B) antibody
  • Cyclin-dependent kinase 4 inhibitor B (cdn2b) antibody
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (cdkn2b) antibody
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b) antibody
  • AV083695 antibody
  • CDK4I antibody
  • cdk4l antibody
  • CDKN2A antibody
  • INK4b antibody
  • MTS2 antibody
  • p14-INK4b antibody
  • P15 antibody
  • p15(INK4b) antibody
  • p15INK4b antibody
  • TP15 antibody

Protein level used designations for CDKN2B

Cyclin-dependent kinase 4 inhibitor B , CDK inhibitory protein , CDK4B inhibitor , MTS-2 , cyclin-dependent kinase 4 inhibitor B , cyclin-dependent kinases 4 and 6 binding protein , multiple tumor suppressor 2 , p14-INK4b , p14_CDK inhibitor , p14_INK4B , p15 CDK inhibitor , p15-INK4b , p15_INK4B , cyclin-dependent kinase inhibitor p15 , cyclin-dependent kinase inhibitor p15INK4b , cyclin-dependent kinase inhibitor protein , Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4) , cyclin dependant kinase inhibitor , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2B , cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4) , p15INK4b tumor suppressor

709209 Macaca mulatta
100196147 Salmo salar
448767 Xenopus (Silurana) tropicalis
779240 Xenopus laevis
1030 Homo sapiens
12579 Mus musculus
25164 Rattus norvegicus
481563 Canis lupus familiaris
397227 Sus scrofa
527124 Bos taurus
395076 Gallus gallus
Selected quality suppliers for anti-CDKN2B (CDKN2B) Antibodies
Did you look for something else?